PRODUCT INFORMATION



13,14-dihydro-15-keto Prostaglandin E₁-d₄

Item No. 9000288

Formal Name:	9,15-dioxo-11α-hydroxy-prostan-1-oic-	
	3,3,4,4-d ₄ acid	
Synonyms:	13,14-dh-15-k PGE ₁ -d ₄	0
MF:	$C_{20}H_{30}O_5D_4$	
FW:	358.5	
Chemical Purity:	≥98% (13,14-dh-15-k PGE₁)	
Deuterium	±	
Incorporation:	\geq 99% deuterated forms (d ₁ -d ₄); \leq 1% d ₀	но Т ў ў
Supplied as:	A solution in methyl acetate	0
Storage:	-20°C	
Stability:	≥2 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

13,14-dihydro-15-keto Prostaglandin E_1 -d₄ (13,14-dh-15-k PGE₁-d₄) is intended for use as an internal standard for the quantification of 13,14-dh-15-k PGE₁ by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

13,14-dh-15-k PGE₁-d₄ is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of 13,14-dh-15-k PGE₁-d₄ in these solvents is approximately 50 mg/ml

Description

13,14-dh-15-k PGE_1 is a metabolite of PGE_1 with much reduced biological activity.¹⁻³ Steady state plasma concentrations are about 10 pg/ml.¹ 13,14-dh-15-k PGE₁ is a weak inhibitor of ADP-induced platelet aggregation in human PRP and washed platelets with IC₅₀ values of 54 and 200 μ M, respectively, compared to PGE₁ which has an IC₅₀ value of 40 nM.⁴

References

- 1. Leonhardt, A., Krauss, M., Gieler, U., et al. In vivo formation of prostaglandin E₁ and prostaglandin E₂ in atopic dermatitis. Br. J. Dermatol. 136(3), 337-340 (1997).
- 2. Hamberg, M. and Samuelsson, B. On the metabolism of prostaglandins E_1 and E_2 in man. J. Biol. Chem. 246(22), 6713-6721 (1971).
- 3. Peskar, B.A., Cawello, W., Rogatti, W., et al. On the metabolism of prostaglandin E₁ administered intravenously to human volunteers. J. Physiol. Pharmacol. 42(3), 327-331 (1991).
- Kobzar, G., Mardla, V., Järving, I., et al. Antiaggregating potency of E-type prostaglandins in human and rabbit platelets. Proc. Estonian Acad. Sci. Chem. 40(N3), 179-180 (1991).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/11/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM